Protocol Ledger

NCT05490563 · Phase II/III · TERMINATED

STRIDES - a Clinical Research Study of an Investigational New Drug to Treat Spinocerebellar Ataxia

Interventional Phase II/III clinical trial protocol NCT05490563 sponsored by Seelos Therapeutics in Rare Genetic, Women's Health, and Other, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2022-06-03 Enrollment: 23 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT05490563
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)23 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT05490563
Protocol FieldVerified Registry Value
NCT IdentifierNCT05490563
Consolidated Lead SponsorSeelos Therapeutics
Therapeutic Condition CohortRare Genetic, Women's Health, and Other
Clinical Trial PhasePhase II/III
Overall Recruitment StatusTERMINATED
Registered Enrollment23 participants (ACTUAL)
Registered Start Date2022-06-03
WhyStopped ClassificationSafety / Toxicity / Adverse Events

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Rare Genetic, Women's Health, and Other Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI